Sarah Cannon Research Partner
Research Partner with SCRI
In June 2011, The Tampa Bay Heart Institute at Northside Hospital partnered with Sarah Cannon Research Institute (SCRI), one of the largest global clinical research programs. This partnership designates TBHI as a cardiovascular clinical research strategic site.
SCRI’s rapidly expanding cardiovascular research network enables hospitals and physician practices to develop their research programs and provides the opportunity for patients to consider participation in clinical trials in their own community.
The benefits of this relationship are far-reaching for Northside patients and their families. Together, we will now be able to provide patients with:
- Expanded treatment options -- improved local access to clinical trials and leading-edge treatments that can be administered close to home;
- Consistent care -- an increased ability to retain continuity of care with physicians they know and trust; and
- Innovative medicine -- the ability to participate in investigator-initiated trials with promising drug combination therapies.
As part of the agreement, SCRI will help manage industry sponsored and investigator initiated clinical trials in interventional cardiology and electrophysiology. In addition, the staff will have access to SCRI’s physician experts and clinical research team.
Current Research Trials at Northside Hospital:
ION: Eluting Platinum Chromium Coronary Stent System US Post-Approval StudyPrincipal Investigator: Dr Andrew Rosenthal, Sub-Investigator: Dr Minor, Dr Walsh, Dr MukayedSponsor: Boston ScientificStatus: Closed to enrollment, 39 patients enrolled at this site and currently in follow up (5 years)
CABANA: Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation TrialPrincipal Investigator: Dr Robert Sheppard, Sub-Investigator: Dr CardonaSponsor: National Heart Lung and Blood Institute, Investigator Initiated Trial Mayo Clinic, Dr Douglas Packer, study management DCRIStatus: Open to enrollment.
QuadPas: Quadripolar Pacing Post Approval Study – Quadra CRT-D and Quartet LV Lead (10 programmable vectors)Principal Investigator: Dr Robert Sheppard, Sub-Investigator: Dr Francisco CardonaSponsor: St Jude MedicalStatus: Open to enrollment, currently 11 patients enrolled.
SAVI-PCI: Efficacy of Tirofiban High-Dose Bolus plus shortened Infusion duration vs. Label-dosing Eptifibatide in patients undergoing PCIPrincipal Investigator: Dr Andrew Rosenthal, Sub-Investigator: Dr Walsh, Dr MukayedSponsor: Medicure Inc.Status: Open to enrollment.
Upcoming Research Trials at Northside Hospital:
EVOLVE II -- Bioabsorbable Stent: Bioabsorbable StentPrincipal Investgator Dr Andrew Rosenthal, Sub-Investigator: Dr Walsh, Dr MukayedSponsor: Boston ScientificStatus: IRB approved, awaiting site initiation from sponsor.
ABLATE Post-Approval Study: Atricure Synergy Ablation lesions for non-paroxysmal forms of atrial fibrillation treatment duringconcomitant on-pump endo-epicardial cardiac surgery.Principal Investigator: Dr Michael DeFrain, Sub-Investigator: Dr BryanSponsor: AtricureStatus: IRB approved, awaiting site initiation from sponsor.
Outpatient-focused trials: Amgen Protocol 20110118 Double-blind, Randomized, Placebo-controlled, Multi-center study assessing the impact of additional LDL-Cholesterol Reduction on Major Cardiovascular Events when AMG 145 is used in combination with statin therapy in patients with clinically evident Cardiovascular DiseasePrincipal Investigator: Dr Robert Sanchez, Sub-Investigator: Dr Peter WassmerPreliminary site initiation completed by sponsor. Investigator Meeting planned for beginning February 2013. Enrollment is planned to start February 2012 per sponsor.
GLORIA: Sponsor: Boehringer-IngelheimPrincipal Investigator: Dr Francisco Cardona, Sub-Investigator: Dr Robert SheppardAwaiting site selection